Boston, MA 08/07/2014 (wallstreetpr) – In the case involving illegal marketing of a drug associated with organ transplant, Pfizer Inc. (NYSE:PFE) will shed out $35 million from its pocket. The amount shall be paid in order to settle allegations from 42 different states that the company’s subsidiary, Wyeth Pharmaceuticals marketed this drug for unlawful uses. Among 42 states which received money from the company, three of them also include New Jersey, Pennsylvania, and Delaware.
It was alleged that the drug called Rapamune went through off-label marketing and was promoted in an improper and unlawful manner for lung, heart and liver transplants, along with use in non-permissible drug combinations.
Statement From The Attorney General Of The States
The attorney general of these 42 states, on August 6, 2014 said that Wyeth, which was taken over by Pfizer Inc. (NYSE:PFE) in the year 2009 in a transaction worth $68 billion, gave training to its sales representatives for encouraging doctors to prescribe to their patents, a drug called Rapamune for uses apart from prevention of rejecting transplanted kidneys.
Rapamune: The Talked About Drug
Rapamune was cleared in approval by the U.S. Food and Drug Administration in the year 1999, but only for uses in the patients of kidney transplant. Therefore, making use of this drug or promoting it for uses other than the ones that are approved by FDA is strictly unlawful.
Settlement Of The Case
In this context, Pfizer Inc. (NYSE:PFE) agreed in July 2013 that it would shed out approximately $491 million in order to steadfast like-wise investigations undertaken by the Department of Justice.
In this milieu, however, Pfizer Inc. (NYSE:PFE) gave a statement on August 6, 2014 that the alleged activities concerning Rapamune took place before acquisition of Wyeth Pharmaceuticals. Also, Pfizer said in a statement that Wyeth had not disclosed about the liability or any transgression as a part of its agreement or settlement.
